Related changes
← GFRA3
Enter a page name to see changes on pages linked to or from that page. (To see members of a category, enter Category:Name of category). Changes to pages on your Watchlist are in bold.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
17 May 2024
N 17:21 | Quizartinib diffhist +8,825 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=quizartinib |aOrAn=a |drugClass=a kinase inhibitor |indicationType=treatment |indication=adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test. |hasBlackBoxWarning=Yes |adverseReactions=The most common (>20%) adverse reactions, including laboratory abnormalities, are decreased lymphocytes, decreased potassium,...") |
16 May 2024
|
14:34 | Trofinetide 6 changes history +5,945 [Alen Antony (6×)] | |||
|
14:34 (cur | prev) +1,803 Alen Antony talk contribs | ||||
|
14:19 (cur | prev) −1 Alen Antony talk contribs Tag: Manual revert | ||||
|
03:47 (cur | prev) +1 Alen Antony talk contribs | ||||
|
03:46 (cur | prev) +2,158 Alen Antony talk contribs | ||||
|
03:29 (cur | prev) +912 Alen Antony talk contribs | ||||
|
03:09 (cur | prev) +1,072 Alen Antony talk contribs |
15 May 2024
|
04:40 | Trofinetide 2 changes history +176 [Alen Antony (2×)] | |||
|
04:40 (cur | prev) +41 Alen Antony talk contribs | ||||
|
04:40 (cur | prev) +135 Alen Antony talk contribs |
2 May 2024
N 15:29 | Trofinetide diffhist +74 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=trofinetide }}") |
29 April 2024
|
N 15:25 | Trastuzumab emtansine 2 changes history +40,575 [Alara E. Dagsali (2×)] | |||
|
15:25 (cur | prev) −35 Alara E. Dagsali talk contribs | ||||
N |
|
15:23 (cur | prev) +40,610 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=AlaraE.Dagsali |genericName=ado-trastuzumab emtansine |indicationType=treatment |indication=the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. the adjuvant treatment...") |